Treatment-related mortality in children with acute lymphoblastic leukaemia in a low-middle income country.

J Pak Med Assoc

Department of Pediatric Hematology/Oncology and BMT, The Children's Hospital and Institute of Child Health, Lahore, Pakistan.

Published: October 2021

Objective: To determine the proportion of treatment-related mortality among mortalities of paediatric acute lymphoblastic leukaemia and to identify probable causes and risk factors.

Methods: The observational retrospective study was conducted in February-March 2019 at the Department of Paediatric Haematology-Oncology and Bone Marrow Transplant, the Children's Hospital and the Institute of Child Health, Lahore, Pakistan, and comprised data of all paediatric patients of acute lymphoblastic leukaemia who expired during treatment from January 2017 till September 2018. Death due to relapse and deaths before treatment were excluded. Data was analysed using SPSS 16.

Results: Of the 247 deaths during the study period, 144(58.3%) were treatment-related mortality cases; 81(56.2%) males and 63(43.8%) females with an overall mean age of 5.0±3.83 years. The commonest cause was sepsis 126(87.5%), followed by haemorrhagic complications 11(7.6%), drug toxicity 4(2.8%), tumour lysis syndrome 2(1.4%) and thromboembolism 1(0.7%). Significant factors associated with treatment-related mortality were weight-for-age, immunophenotype, the reason for admission, and absolute neutrophil count (p<0.05).

Conclusions: Treatment-related mortality, though potentially avoidable, was found to be a major cause of death among paediatric patients of acute lymphoblastic leukaemia, and sepsis was the most common cause.

Download full-text PDF

Source
http://dx.doi.org/10.47391/JPMA.796DOI Listing

Publication Analysis

Top Keywords

treatment-related mortality
16
acute lymphoblastic
12
lymphoblastic leukaemia
12
treatment-related
4
mortality children
4
children acute
4
leukaemia low-middle
4
low-middle income
4
income country
4
country objective
4

Similar Publications

Attitudes, beliefs and preferences surrounding home-based exercise programs in endometrial cancer patients receiving treatment.

Gynecol Oncol Rep

February 2025

University of Iowa, Department of Psychological and Brain Sciences, Holden Comprehensive Cancer Center, G60 Psychological and Brain Sciences Building, 340 Iowa Ave, Iowa City, IA 52242, USA.

Background: Despite recommendations, exercise participation among endometrial cancer survivors remains low. Previous interventions focused on weight loss or in-person programs with limited reach. Regular exercise, regardless of weight change, reduces mortality risk and improves functionality.

View Article and Find Full Text PDF

Introduction Laryngeal cancer (LC) is the most common malignancy in otolaryngology, comprising 30-40% of head and neck malignancies. With an increasing incidence worldwide over the past few decades, LC has resulted in substantial strain on the NHS. There have been notable advancements in the treatment of LC over the years, particularly with the adoption of non-surgical methods, which emerged after the 1991 study conducted by the Veterans Affairs.

View Article and Find Full Text PDF

Assessment of Treatment Outcomes and Associated Factors Among Pediatric Patients With Burkitt Lymphoma at Kenyatta National Hospital.

Cancer Rep (Hoboken)

January 2025

Department of Pharmacology, Clinical Pharmacy and Pharmacy Practices, Faculty of Health Sciences, University of Nairobi, Nairobi, Kenya.

Background: In developing countries, the treatment outcomes of Burkitt lymphoma are poor due to the poorly equipped healthcare systems. In addition, there is limited comprehensive data within the African continent, including Kenya, about the outcomes of treatment for this cancer.

Aims: To assess treatment outcomes and variables associated with an increased risk of death from disease progression or treatment-related toxicities among Burkitt lymphoma pediatric patients at the Kenyatta National Hospital (KNH).

View Article and Find Full Text PDF

Importance: There is a lack of long-term efficacy and safety data on hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN) and on RNA interference (RNAi) therapeutics in general. This study presents the longest-term data to date on patisiran for hATTR-PN.

Objective: To present the long-term efficacy and safety of patisiran in adults with hATTR-PN.

View Article and Find Full Text PDF

Background: In the fifth National Wilms Tumor Study, patients received vincristine and dactinomycin (VA) without radiation for stage I focal anaplastic Wilms tumor (FAWT) and VA plus doxorubicin (DD4A) and radiation for stage II-IV FAWT. Four-year event-free survival (EFS) and overall survival (OS) for stage I FAWT were 67.5% and 88.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!